Bristol Myers Squibb (BMY) Accounts Payables (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Accounts Payables data on file, last reported at $4.2 billion in Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.2 billion, up 5.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 billion (up 5.8% YoY), and the FY2025 annual result was $3.6 billion, down 0.75% from the prior year.
• Accounts Payables grew to $4.2 billion in Q1 2026 per BMY's latest filing, from $3.6 billion in the prior quarter.
• Over five years, Accounts Payables peaked at $5.4 billion in Q2 2025 and troughed at $2.6 billion in Q3 2022.
• A 5-year average of $3.5 billion and a median of $3.5 billion in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables dropped 20.14% in 2022, then jumped 44.68% in 2025.
• A 5-year view of Accounts Payables shows it stood at $3.0 billion in 2022, then gained by 7.2% to $3.3 billion in 2023, then climbed by 10.52% to $3.6 billion in 2024, then decreased by 0.75% to $3.6 billion in 2025, then increased by 18.43% to $4.2 billion in 2026.
• Business Quant data shows BMY's Accounts Payables at $4.2 billion in Q1 2026, $3.6 billion in Q4 2025, and $4.3 billion in Q3 2025.